FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

BACKGROUND: Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau proteins via immunotherapy is a promising strategy for disease-modi...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Petr, Schmidt, Reinhold, Kontsekova, Eva, Kovacech, Branislav, Smolek, Tomas, Katina, Stanislav, Fialova, Lubica, Prcina, Michal, Parrak, Vojtech, Dal-Bianco, Peter, Brunner, Martin, Staffen, Wolfgang, Rainer, Michael, Ondrus, Matej, Ropele, Stefan, Smisek, Miroslav, Sivak, Roman, Zilka, Norbert, Winblad, Bengt, Novak, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201586/
https://www.ncbi.nlm.nih.gov/pubmed/30355322
http://dx.doi.org/10.1186/s13195-018-0436-1

Ejemplares similares

Ejemplares similares